N/A N=102 Healthy Body Healthy Souls in the Marshallese Population
Weight Loss · Pre Diabetes · Overweight and Obesity
Primary: Mean Percent Body Weight (Pounds) Change — 0.88; 0.53; -1.06 percent weight change — p=0.1013
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=28 Effect of Oligofructose on Appetite in Overweight Subjects
Appetite Regulation · Obesity
Primary: Subjective Appetite Ratings in Hunger Compared to Baseline — 4.8; 3.6; 3.6; 4.1 cm — p=0.135
Phase 3 N=458 Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
Ankylosing Spondyloarthritis
Primary: The Proportion of Participants Who Achieve an ASAS 20 Response (Assessment of SpondyloArthritis International Society Criteria) — 178; 56 Participants — p=<.0001
Phase 1 N=16 The Stanford Parkinson's Disease Plasma Study
Parkinson Disease(PD)
Primary: Number of Related and Unrelated Adverse Events — 14; 3; 36 events
Phase 2 N=20 Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: Radiographic Response (RR) — 9; 0; 9; 9 Participants
Phase 2 N=199 Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
Paroxysmal Supraventricular Tachycardia (PSVT)
Primary: The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug Administration — 20; 15; 20; 13 Participants — p=<0.05
Phase 1 N=13 Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome
LQT2 Syndrome
Primary: Change From Baseline in Standard 12-Lead Electrocardiogram (ECG) Daytime QT Interval Corrected For Heart Rate Using The Fridericia Formula (QTcF) (AUC0-8)/8 at Day 3…
N/A N=50 Ultrasound-Guided Peripheral Venous Access Using AccuCath
Intravenous Access
Primary: First Attempt Success Rate — 17; 11 Participants
Phase 2 N=11 Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
Prostate Cancer
Primary: Overall Clinical Benefit — 1; 4; 1; 2 Participants
N/A N=25 A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer
Head and Neck Cancer · Oropharyngeal Cancer
Primary: Dosimetric Comparisons With Adaptive Radiotherapy (ART) Planning to Intensity-modulated Radiation Therapy (IMRT) Planning — -2.8; -3.8; -3.9; -9 percentage in mean dose…
N/A N=164 Safety and Effectiveness of JUVÉDERM® VOLUMA® With Lidocaine for Improvement of Volume and Aesthetic Appearance of the Nose in Chinese Adults
Nose Enhancement
Primary: Volume Change From Baseline in the Nose Area — -0.005; 2.032 cubic centimeters (cc) — p=<0.0001
Phase 2 N=99 Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
Pancreatic Tumours · Midgut Neuroendocrine Tumours
Primary: Median Progression Free Survival (PFS) — 5.6; 8.3 months
Phase 2 N=95 The Effect of Farlong® NotoGinseng™ (Ginseng Plus®) on Cholesterol and Blood Pressure
Hyperlipidemias · Hypertension
Primary: The Difference in Serum LDL-C From Baseline to Week 12 Between Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng Extract) and Placebo After 12 Weeks of…
Phase 1 N=11 Minimally Invasive Sensing of Beta-lactam Antibiotics
Healthy Volunteers
Primary: Assessment of the Biosensors Ability to Track Phenoxymethylpenicillin Concentrations Compared to Observations Made by Microdialysis and Blood Sampling — -0.16 mg/L
Phase 2 N=1 Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Peripheral T-cell Lymphoma · Cutaneous T-cell Lymphoma
Primary: Global Composite Response (Skin, Blood, Lymph Nodes)as Determined by Skin Evaluations, Blood Counts and PET/CT Imaging — 260; 260; 232 days